Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Impact of schizophrenia and related disorders on mortality from breast cancer: A population-based cohort study in Denmark, 1995-2011

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{95dd0476d0154337a536c0f9ab548bd2,
title = "Impact of schizophrenia and related disorders on mortality from breast cancer: A population-based cohort study in Denmark, 1995-2011",
abstract = "OBJECTIVES: To investigate overall and breast cancer-specific mortality in early-stage breast cancer patients with and without schizophrenia or related disorders.METHODS: We used Danish national registers to identify all women with no prior history of cancer or organic mental disorders, who were diagnosed with early-stage breast cancer 1995-2011. Logistic regression models were used to calculate the odds ratios (ORs) for not being allocated to guideline treatment. Cox regression models were used to compute hazard ratios (HRs) for overall and breast cancer-specific deaths among women allocated or not allocated to guideline treatment.RESULTS: We identified 56,152 women with early-stage breast cancer diagnosed in 1995-2011, of whom 499 women also had been diagnosed with schizophrenia or related disorders. The likelihood of women with schizophrenia or related disorders for not being allocated to guideline treatment was increased (adjusted OR, 1.50; 95{\%} confidence interval (CI), 1.15-1.94). The adjusted HR for all-cause mortality was 1.55; 95{\%} CI, 1.32-1.82 and 1.12 (95{\%} CI, 0.98-1.50) for breast cancer-specific mortality; women allocated to guideline treatment had an adjusted HR for breast cancer-specific death of 1.42 (95{\%} CI, 1.11-1.82). The adjusted HR for death due to unnatural causes was 3.67 (95{\%} CI, 1.80-7.35).CONCLUSION: The survival of women with schizophrenia or related disorders after breast cancer is significantly worse than that of women without these disorders. These patients are less likely to be allocated to guideline treatment, and, among those who are, mortality from both breast cancer and other causes is increased.",
author = "Dalton, {Susanne Oksbjerg} and Suppli, {Nis Palm} and Marianne Ewertz and Niels Kroman and Luigi Grassi and Christoffer Johansen",
note = "Copyright {\circledC} 2018. Published by Elsevier Ltd.",
year = "2018",
month = "8",
doi = "10.1016/j.breast.2018.06.002",
language = "English",
volume = "40",
pages = "170--176",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

RIS

TY - JOUR

T1 - Impact of schizophrenia and related disorders on mortality from breast cancer

T2 - A population-based cohort study in Denmark, 1995-2011

AU - Dalton, Susanne Oksbjerg

AU - Suppli, Nis Palm

AU - Ewertz, Marianne

AU - Kroman, Niels

AU - Grassi, Luigi

AU - Johansen, Christoffer

N1 - Copyright © 2018. Published by Elsevier Ltd.

PY - 2018/8

Y1 - 2018/8

N2 - OBJECTIVES: To investigate overall and breast cancer-specific mortality in early-stage breast cancer patients with and without schizophrenia or related disorders.METHODS: We used Danish national registers to identify all women with no prior history of cancer or organic mental disorders, who were diagnosed with early-stage breast cancer 1995-2011. Logistic regression models were used to calculate the odds ratios (ORs) for not being allocated to guideline treatment. Cox regression models were used to compute hazard ratios (HRs) for overall and breast cancer-specific deaths among women allocated or not allocated to guideline treatment.RESULTS: We identified 56,152 women with early-stage breast cancer diagnosed in 1995-2011, of whom 499 women also had been diagnosed with schizophrenia or related disorders. The likelihood of women with schizophrenia or related disorders for not being allocated to guideline treatment was increased (adjusted OR, 1.50; 95% confidence interval (CI), 1.15-1.94). The adjusted HR for all-cause mortality was 1.55; 95% CI, 1.32-1.82 and 1.12 (95% CI, 0.98-1.50) for breast cancer-specific mortality; women allocated to guideline treatment had an adjusted HR for breast cancer-specific death of 1.42 (95% CI, 1.11-1.82). The adjusted HR for death due to unnatural causes was 3.67 (95% CI, 1.80-7.35).CONCLUSION: The survival of women with schizophrenia or related disorders after breast cancer is significantly worse than that of women without these disorders. These patients are less likely to be allocated to guideline treatment, and, among those who are, mortality from both breast cancer and other causes is increased.

AB - OBJECTIVES: To investigate overall and breast cancer-specific mortality in early-stage breast cancer patients with and without schizophrenia or related disorders.METHODS: We used Danish national registers to identify all women with no prior history of cancer or organic mental disorders, who were diagnosed with early-stage breast cancer 1995-2011. Logistic regression models were used to calculate the odds ratios (ORs) for not being allocated to guideline treatment. Cox regression models were used to compute hazard ratios (HRs) for overall and breast cancer-specific deaths among women allocated or not allocated to guideline treatment.RESULTS: We identified 56,152 women with early-stage breast cancer diagnosed in 1995-2011, of whom 499 women also had been diagnosed with schizophrenia or related disorders. The likelihood of women with schizophrenia or related disorders for not being allocated to guideline treatment was increased (adjusted OR, 1.50; 95% confidence interval (CI), 1.15-1.94). The adjusted HR for all-cause mortality was 1.55; 95% CI, 1.32-1.82 and 1.12 (95% CI, 0.98-1.50) for breast cancer-specific mortality; women allocated to guideline treatment had an adjusted HR for breast cancer-specific death of 1.42 (95% CI, 1.11-1.82). The adjusted HR for death due to unnatural causes was 3.67 (95% CI, 1.80-7.35).CONCLUSION: The survival of women with schizophrenia or related disorders after breast cancer is significantly worse than that of women without these disorders. These patients are less likely to be allocated to guideline treatment, and, among those who are, mortality from both breast cancer and other causes is increased.

U2 - 10.1016/j.breast.2018.06.002

DO - 10.1016/j.breast.2018.06.002

M3 - Journal article

VL - 40

SP - 170

EP - 176

JO - Breast

JF - Breast

SN - 0960-9776

ER -

ID: 54866980